OrthoPediatrics received FDA 510(k) clearance to market the 3P Pediatric Plating Platform Small-Mini System, the second of several systems in the 3P family.
3P Small-Mini System is a versatile plate and screw solution featuring variable-angle locking implants designed specifically for pediatric orthopedic surgeons. It supports a wide range of trauma and deformity surgeries with procedure-specific and utility plates in sizes 2.0mm, 2.4mm, 2.7mm, and 3.5mm. Featuring specialized instruments, streamlined tray layouts, and color-coding for enhanced surgical flow, the system aims to optimize operating room efficiency. As the second release in the 3P Pediatric Plating Platform, it follows the 3P Hip System.
CEO David Bailey said, “We remain focused on delivering a comprehensive portfolio of innovative orthopedic solutions to expand our support to more pediatric patients. This is the 6th FDA approval for the company in 2025, and was received ahead of our expectations, thanks to the dedication and excellence of our R&D team.”
OrthoPediatrics received FDA 510(k) clearance to market the 3P Pediatric Plating Platform Small-Mini System, the second of several systems in the 3P family.
3P Small-Mini System is a versatile plate and screw solution featuring variable-angle locking implants designed specifically for pediatric orthopedic surgeons. It supports a wide range of...
OrthoPediatrics received FDA 510(k) clearance to market the 3P Pediatric Plating Platform Small-Mini System, the second of several systems in the 3P family.
3P Small-Mini System is a versatile plate and screw solution featuring variable-angle locking implants designed specifically for pediatric orthopedic surgeons. It supports a wide range of trauma and deformity surgeries with procedure-specific and utility plates in sizes 2.0mm, 2.4mm, 2.7mm, and 3.5mm. Featuring specialized instruments, streamlined tray layouts, and color-coding for enhanced surgical flow, the system aims to optimize operating room efficiency. As the second release in the 3P Pediatric Plating Platform, it follows the 3P Hip System.
CEO David Bailey said, “We remain focused on delivering a comprehensive portfolio of innovative orthopedic solutions to expand our support to more pediatric patients. This is the 6th FDA approval for the company in 2025, and was received ahead of our expectations, thanks to the dedication and excellence of our R&D team.”
Copy to clipboard 
